Verve Therapeutics Overview
Verve Therapeutics (VERV) has a P/E ratio of -4.72, below the Healthcare sector average of 24.78.
Get informed when a big investor buys or sells
+ Follow-4.72
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Verve Therapeutics (VERV) currently reports a P/E ratio of -4.72. That is below the Healthcare sector average of 24.78. Use the charts on this page to explore Verve Therapeutics's P/E ratio history and peer comparisons.
Verve Therapeutics's P/E ratio of -4.72 is lower than the Healthcare sector average of 24.78. That is roughly 119.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Verve Therapeutics's market price to a fundamental measure such as earnings, sales, or book value. At -4.72, VERV can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -4.72, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 24.78. From there, open related valuation or income-statement pages for Verve Therapeutics, and consider following VERV for alerts when major investors trade the stock.
Verve Therapeutics is classified in the Healthcare sector. On P/E ratio, it currently shows -4.72 versus a sector average near 24.78. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing VERV with unrelated industries.
